| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL | /s/ Mark Worthington, Attorney-in-Fact on behalf of Kevin Church | 2025-07-02 | 0001822499 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ATHA | Common Stock | Award | $2.31K | +10K | +7.65% | $0.23 | 141K | May 19, 2025 | Direct | F1, F2, F3 |
| transaction | ATHA | Common Stock | Options Exercise | $0 | +36.7K | +26.05% | $0.00 | 177K | Jun 30, 2025 | Direct | |
| transaction | ATHA | Common Stock | Sale | -$2.5K | -8.53K | -4.81% | $0.29 | 169K | Jul 1, 2025 | Direct | F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ATHA | Restricted Stock Units | Options Exercise | $0 | -36.7K | -50% | $0.00 | 36.7K | Jun 30, 2025 | Common Stock | 36.7K | Direct | F6, F7, F8 |
| Id | Content |
|---|---|
| F1 | The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"),for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2024 through May 19, 2025. This transaction is exempt under Rule 16b-3(c). |
| F2 | The Purchase Period ended March 19, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2024. |
| F3 | In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 19, 2025. |
| F4 | Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. |
| F5 | The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F6 | RSUs convert into common stock on a one-for-one basis. |
| F7 | Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. |
| F8 | On October 1, 2024, the reporting person was granted 110,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. |